About

Over the years, advances in biomaterials research have led to high throughput and complex microphysiological systems (MPSs), e.g., organoid models, organ-on-a chip devices, bioreactors, and other technologies that minimize the use of in vivo animal models. This panel will be a point-counterpoint panel with representatives from industry, academia, and regulatory agencies to debate the utility of in vitro and in vivo models. Challenges for MPSs and strategies for overcoming those hurdles will be discussed, with a focus on how the development of industry standards for testing and demonstrating the efficacy of MPSs could impact the translational potential of preclinical data. Audience participation through polling software will also be used to assess the consensus on support for speakers’ viewpoints.